Premium
Novel agents for muscle‐invasive and advanced urothelial cancer
Author(s) -
Sonpavde Guru,
Ross Robert,
Powles Thomas,
Sweeney Christopher J.,
Hahn Noah,
Hutson Thomas E.,
Galsky Matthew D.,
Lerner Seth P.,
Sternberg Cora N.
Publication year - 2008
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2007.07326.x
Subject(s) - urothelial cancer , bladder cancer , medicine , cancer research , urology , cancer
Conventional front‐line platinum‐based combination chemotherapy yields high response rates but suboptimal long‐term outcomes for advanced urothelial cancer. Salvage therapy is an unmet need, with disappointing outcomes. The profusion of novel biological agents offers the promise of improved outcomes. Neoadjuvant therapy before cystectomy for muscle‐invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed.